Formulation development and evaluation of sustained release bilayer tablet containing pioglitazone and glucosum in management of hypoglycemic diabetes.

The present work involves the formulation development, optimization and In-vitro evaluation of bilayer tablet containing Lansoprazole in the immediate release layer and Amoxycillin in the sustained release layer, using sodium starch glycolate as a super disintegrant for the immediate release layer and the hydrophilic matrix HPMC K100M, hydrophobic matrix Ethyl cellulose are used in the sustained release layer. Bilayer tablet showed as initial burst effect to provide dose of immediate release layer Lansoprazole to control the acid secretion level and the sustained release of Amoxycillin for 24 hours. Immediate and sustained release tablets were formulated by wet granulation method because of the poor flow property of the blends. The prepared bilayer tablet was evaluated for their precompression parameters, physical characteristics like hardness, friability, uniformity of weight, uniformity of drug content, swelling index, In-vitro floating studies and In-vitro drug release. The release of the lansoprazole from the immediate release layer was found to be 97.46 ± 0.15% in 15minutes. The release of Amoxycillin Trihydrate for the sustained release floating layer was found to be 98.25 ± 0.14% in 12 hours. Lansoprazole potentiate the effect of Amoxycillin. Hence the bilayer tablets of Lansoprazole and Amoxycillin were used to improve patient compliance towards the effective management of ulcer. Keywords: bilayer tablet, Lansoprazole, and Amoxycillin, sustained release

Download Full-text

Formulation development and invitro evaluation of elvitegravir sustained release using solid dispersions

Research Journal of Pharmacy and Technology ◽

10.5958/0974-360x.2020.01031.8 ◽

2020 ◽

Vol 13 (12) ◽

pp. 5909-5913

Author(s):

Mohammad Akthar Sulthana ◽

Mangulal Kethavath ◽

Fazil Ahmad ◽

Abeer Mohammed Al-Subaie

Keyword(s):

Sustained Release ◽

Solid Dispersions ◽

Formulation Development

Download Full-text

Studies on Formulation Development of Mucoadhesive Sustained Release Itraconazole Tablet Using Response Surface Methodology

AAPS PharmSciTech ◽

10.1208/s12249-008-9119-8 ◽

2008 ◽

Vol 9 (3) ◽

Cited By ~ 14

Author(s):

Ashwini Madgulkar ◽

Shivajirao Kadam ◽

Varsha Pokharkar

Keyword(s):

Response Surface Methodology ◽

Sustained Release ◽

Response Surface ◽

Formulation Development

Download Full-text

Formulation, Development and Evaluation of Bilayer Floating Tablet of Gemfibrozil

Journal of Drug Delivery and Therapeutics ◽

10.22270/jddt.v9i4-s.3401 ◽

2019 ◽

Vol 9 (4) ◽

pp. 574-578

Author(s):

Mohammad Faizan Mohammad Gufran ◽

Sailesh Kumar Ghatuary ◽

Reena Shende ◽

Prabhat Kumar Jain ◽

Geeta Parkhe

Keyword(s):

Drug Release ◽

Sustained Release ◽

Hydroxypropyl Methylcellulose ◽

Immediate Release ◽

In Vitro Dissolution ◽

Log P ◽

Physical Parameters ◽

Direct Compression ◽

Formulation Development ◽

Compression Technique

Formulation development is an important part of drug design and development. Bioavailability and bioequivalence are totally dependent on formulation development. Now-a-days formulation development is done by following QbD (Quality by Design).The aim of present study is to formulate Gemfibrozil (Gem) sustained release (SR) and immediate release (IR) bilayer tablet by different concentration of Hydroxypropyl methylcellulose (HPMC) and HPMC K 100 M to control the release pattern. The sustained release layer of Gem was prepared by using different grades of HPMC like, HPMC K-15, HPMC K-4 along with other excipients by direct compression technique. The immediate release layer of Gem was prepared by Cross carmellose sodium, Crospovidone and Sodium starch glycolate by direct compression technique. The powders were evaluated for their flow properties and the finished tablets were evaluated for their physical parameters. The both immediate release and sustained release layers of Gem were characterized by FT-IR and in vitro dissolution studies. The drug release study of Gem was evaluated using USP-II paddle type dissolution apparatus. The release rate of Gem in immediate release layer was studied for 15 min in 0.1 N HCL media and that of Gem in sustained release layer was studied for 12 h in 0.1 N HCL. From the nine batches F6 batch showed good release behaviour 99.85% of drug is released over 12 hours. Gem belongs to BCS Class II (log P 3.6) with poor solubility and high permeability resulting in limited and variable bioavailability. Total four trial batches of each drug have been manufactured to optimize and develop a robust and stable formulation, the stability studies of the products also comply with ICH guideline. Keywords: Bilayer floating tablets, Gemfibrozil, Biphasic drug release, HPMC K 15.

Download Full-text

Formulation, Development and Evaluation of Sustained Release Gastroretentive Floating Tablets of Antidiabetic Drug using Natural Polymers

Asian Journal of Pharmaceutical Education and Research ◽

10.38164/ajper/9.4.2020.87-96 ◽

2020 ◽

Vol 9 (4) ◽

pp. 87-96

Author(s):

Aksah Chandak ◽

Sunil Kumar Shah ◽

Prabhakar Budholiya ◽

C. K. Tyagi

Keyword(s):

Sustained Release ◽

Natural Polymers ◽

Formulation Development ◽

Antidiabetic Drug ◽

Floating Tablets

Download Full-text

Formulation of Sustained Release Hydrophilic Matrix Tablets of Tolcapone with the Application of Sedem Diagram: Influence of Tolcapone’s Particle Size on Sustained Release

Pharmaceutics ◽

10.3390/pharmaceutics12070674 ◽

2020 ◽

Vol 12 (7) ◽

pp. 674 ◽

Cited By ~ 3

Author(s):

Anna Nardi-Ricart ◽

Isaac Nofrerias-Roig ◽

Marc Suñé-Pou ◽

Pilar Pérez-Lozano ◽

Montse Miñarro-Carmona ◽

...

Keyword(s):

Particle Size ◽

Sustained Release ◽

Potent Inhibitor ◽

High Viscosity ◽

Matrix Tablets ◽

Formulation Development ◽

Methyl Transferase ◽

Diagram Method ◽

Hydrophilic Matrix ◽

Amyloid Polyneuropathy

Hydrophilic matrix tablets are a type of sustained release dosage form characterized by distributing a drug in a matrix that is usually polymeric. Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase. In recent years, it has been shown that tolcapone is a potent inhibitor of the amyloid aggregation process of the transthyretin protein, and acts by stabilizing the structure of the protein, reducing the progression of familial amyloid polyneuropathy. The main objective of this study was to obtain a sustained release tablet of tolcapone for oral administration with a preferred dosage regimen of 1 administration every 12 or 24 h and manufactured, preferably, by direct compression. The SeDeM Diagram method has been used for the formulation development of hydrophilic matrix tablets. Given the characteristics of tolcapone, the excipient selected for the formation of the polymeric matrix was a high viscosity hydroxypropylmethylcellulose (Methocel® K100M CR). A decrease in the particle size of tolcapone resulted in a slower dissolution release of the formulation when the concentration of the polymer Methocel® K100M CR was below 29%. These surprising and novel results have given rise to patent number WO/2018/019997.

Download Full-text